Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer

Checkpoint immunotherapy (CPI) has increased survival for some patients with advanced-stage bladder cancer (BCa). However, most patients do not respond. Here, we characterized the tumor and immune microenvironment in pre- and post-treatment tumors from the PURE01 neoadjuvant pembrolizumab immunother...

Descripción completa

Detalles Bibliográficos
Autores principales: Robertson, A. Gordon, Meghani, Khyati, Cooley, Lauren Folgosa, McLaughlin, Kimberly A., Fall, Leigh Ann, Yu, Yanni, Castro, Mauro A. A., Groeneveld, Clarice S., de Reyniès, Aurélien, Nazarov, Vadim I., Tsvetkov, Vasily O., Choy, Bonnie, Raggi, Daniele, Marandino, Laura, Montorsi, Francesco, Powles, Thomas, Necchi, Andrea, Meeks, Joshua J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140274/
https://www.ncbi.nlm.nih.gov/pubmed/37105962
http://dx.doi.org/10.1038/s41467-023-37568-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140274/
https://www.ncbi.nlm.nih.gov/pubmed/37105962
http://dx.doi.org/10.1038/s41467-023-37568-9

Ejemplares similares